PALISADE BIO, INC.

PALI ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
Operating Activities
Net Income $-15.7M $-21.1M $-20.9M $-22.6M $-19.8M $-10.1M $-12.5M $-18.4M
Depreciation & Amortization $289.2K $337.5K $345.5K $348.6K $244.7K $211.1K $187.1K $130.8K
Depreciation $100.0K $161.0K $148.0K $137.0K $126.0K $101.0K $104.0K
Amortization $189.0K $176.0K $197.0K $211.0K $119.0K $110.0K $83.0K
Stock-Based Compensation $1.8M $3.4M $3.0M $4.3M $2.3M $1.6M $3.3M $5.2M
Net Cash from Operating Activities $-13.4M $-15.6M $-18.9M $-11.7M $-10.6M $-8.5M $-8.1M $-10.0M
Investing Activities
Capital Expenditures $11.4K $98.1K $176.3K $207.9K $125.4K $39.2K $196.4K $76.3K
Business Acquisitions
Net Cash from Investing Activities $-94.0K $2.4M $-254.9K $-480.9K $-332.7K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $5.0M $23.7M $13.8M $1.7M $17.3M
Net Change in Cash $-8.5M $10.5M $-7.8M $-4.3M $9.4M $5.1M $-6.9M $7.0M
Free Cash Flow $-13.4M $-15.7M $-19.1M $-11.9M $-10.7M $-8.5M $-8.3M $-10.1M
← Newer Page 2 of 3 Older →